Introduction of new antigens

DIARECT is a primary manufacturer of recombinant and native high quality antigens, covering a wide range of medical conditions. We are proud to introduce three new autoantigens:

  • NXP2 (Cat. No. 31700/31701)
  • SAE1/SAE2 (Cat. No. 31600/31601)
  • Gliadin non recombinant (Cat. No. 31500/31501)

NXP2 and SAE1/SAE2 are the newest addition to DIARECT’s antigens related to polymyositis / dermatomyositis. The non recombinant form of gliadin complements the existing range of celiac disease antigens.

In 2009, Betteridge et al. were the first to associate antibodies that target the small ubiquitin-like modifier activating enzyme subunits 1 and 2 (SAE1/SAE2) with dermatomyositis (DM). These results were later confirmed by others (Tarricone et al. 2012) as well. Autoantibodies directed against nuclear matrix protein 2 (NXP2) have been reported in about 25% of DM and very rarely in polymyositis (PM) patients. These antigens are therefore a valuable tool for further refining categorization of the disease in combination with the other well known markers for that disease.

Discover the complete panel of DIARECT’s polymyositis / dermatomyositis antigens

Monitoring of gliadin antibodies is recommended in patients, who may test negative for anti-tTG autoantibodies, in the screening of populations at risk for celiac disease and other gluten-sensitive enteropathies (Schuppan et al. 2013). In addition to the deaminated recombinant gliadin, DIARECT now offers a gliadin antigen preparation isolated from wheat (Triticum aestivum) grain.

Discover the complete panel of DIARECT’s celiac disease antigens

For additional information on our products, do not hesitate to contact us at info(at)diarect.com or by phone at +49 761 47979-0.

Best regards,
Your DIARECT team